Logo

Real Response to Therapy in Chronic Hepatitis C Virus Patients: A Study From Iran

Author(s):
Najmeh NamazeeNajmeh Namazee1, Shahnaz SaliShahnaz Sali1, Sorour AsadiSorour Asadi1, Mostafa ShafieiMostafa Shafiei2, Bita BehnavaBita Behnava2, Seyed Moayed AlavianSeyed Moayed Alavian2,*
1Infectious Disease and Tropical Medicine Research Center, Shahid Beheshti University of Sciences, IR Iran
2Research Center for Gastroenterology and Liver Diseases, Baqiatallah University of Sciences, editor@hepatmon.com, IR Iran


Hepatitis Monthly:Vol. 12, issue 9; 6151
Published online:Sep 30, 2012
Article type:Research Article
Received:May 10, 2012
Accepted:Jul 06, 2012
How to Cite:Najmeh NamazeeShahnaz SaliSorour AsadiMostafa ShafieiBita BehnavaSeyed Moayed Alavianet al.Real Response to Therapy in Chronic Hepatitis C Virus Patients: A Study From Iran.Hepat Mon.12(9):6151.https://doi.org/10.5812/hepatmon.6151.

Abstract

Background:

Despite significant advances in the treatment of chronic hepatitis C in the past decades, factors which can affect response rates to combination therapy; peginterferon and ribavirin, are still under study and reaching sustained virological response (SVR) is affected by several different factors.

Objectives:

To investigate predictor factors contributing to SVR in Iranian patients.

Patients and Methods:

The present non-randomized, clinical trial was conducted on 100 patients referred to the Tehran Hepatitis Center in 2009-2011. The patients were administered combined peginterferon ?-2a-ribavirin treatment, based on the standard protocol of the Iranian Ministry of Health. At the end of the treatment, the SVR rate and predictors were evaluated.

Results:

The mean age of the patients was 42 and 78% were male. Genotype 1a was the most common (70%) and 55% of patients were treatment nave. The outcomes showed that 12%, 16% and 22% patients were; non-responders, breakthroughs and relapsers, respectively, while 50% of the patients reached SVR. Patients reaching SVR were aged 40 years or lower, they were less likely to have been a non-responder in prior treatments, more likely to have a non-1a genotype and a higher number had an HCV RNA of less than 600 000 IU/ml. The multivariate analysis showed that an age of 40 or lower (OR = 3.74, CI95% = 1.52-9.22), a non-1a genotype (OR = 3.71, CI 95% = 1.40-9.81) and an HCV RNA less than 600 000 IU/ml (OR = 2.52, CI 95% = 1.03-6.15) may be useful SVR predictors.

Conclusions:

The findings of the present study showed that half of the patients reached SVR through combined peginterferon ?-2a and ribavirin treatment, the majority of whom had genotype 3a and a minority had genotype 1a. In addition, an age of 40 or lower, non-1a genotype and a viral load less than 600 000 IU/ml were strong SVR predictors.

Full Text

Full text is available in PDF

comments

Leave a comment here


Crossmark
Crossmark
Checking
Share on
Metrics

Purchasing Reprints

  • Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here (   https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.
Search Relations

Author(s):

Related Articles